Lecture 24: "Democratising Drug Development Through Human Genomics"
In his BIH Lecture on 24 June 2022, Aroon Hingorani talked about the high failure rate in drug development processes and the undesirable consequences for healthcare systems and the pharmaceutical industry. About 96% of programs fail and reviews conclude that the major reason is the lack of efficacy in the intended indication - often unveiled at the final stage. One of the flaws lies in the target-disease matching system: model organisms are often an unreliable predictor of treatment efficacy in humans. Hingorani showed the high potential of human genomics as a tool for drug target identification and validation - an approach that would eventually need a wider societal engagement but could provide a lever for more needs-led than profit-led approach to drug development.
The lecture was moderated by Prof. Birgit Sawitzki (BIH Professor for Translational Immunology)
Further information on this BIH Lecture:
www.bihealth.org/en/notices/o...
About the Speaker:
www.ucl.ac.uk/biosciences/peo...
Further information on the BIH Lecture Series "Frontiers in Translational Medicine - Scientific and Structural Challenges":
www.bihealth.org/en/news/even...